Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Characterization of cell-free circulating DNA in plasma in patients with prostate cancer

Full text
Author(s):
Delgado, Pamela Oliveira [1] ; Alves, Beatriz Costa A. [1] ; Gehrke, Flavia de Sousa [1] ; Kuniyoshi, Renata Kelly [1] ; Wroclavski, Marcelo Langer [2] ; Del Giglio, Auro [1] ; Affonso Fonseca, Fernando Luiz [3, 1]
Total Authors: 7
Affiliation:
[1] FMABC, Oncol Hematol Discipline, Sao Paulo - Brazil
[2] FMABC, Urol Discipline, Sao Paulo - Brazil
[3] Univ Fed Sao Paulo, Dept Biol Sci, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: TUMOR BIOLOGY; v. 34, n. 2, p. 983-986, APR 2013.
Web of Science Citations: 40
Abstract

Cell-free circulating DNA in plasma and serum may serve as a biomarker for malignant tumor detection and follow up in patients with a variety of solid tumors including prostate cancer. In healthy patients, DNA is normally released from an apoptotic source which generates small fragments of cell-free DNA, whereas cancer patients have cell-free circulating DNA that originated from necrosis, autophagy, or mitotic catastrophe. Cell-free circulating DNA levels were measured by a quantitative real-time PCR method with a set of primers targeted to amplify the consensus ALU apoptotic versus necrotic origin. Prostate cancer patients before and 3 months after diagnosis showed cell-free circulating DNA released at apoptotic and non-apoptotic cell death. Interestingly, all patients after 6 months demonstrated DNA released at non-apoptotic cell. The principal source of cell-free circulating DNA is of apoptotic and non-apoptotic cell death. However, during treatment, this feature could change. Therefore, the study of cell-free circulating DNA would be important to follow the evolution of the disease during the treatment. (AU)